Hepatitis Monthly

Published by: Kowsar

Plasma Zinc Level in Hepatitis C Patients With or Without Beta Thalassemia Major; Is There Any Difference?

Mohammad Abbasinazari 1 , * , Bita Behnava 2 , Yunes Panahi 3 , Azita Hajhossein Talasaz 4 , Shima Salimi 2 , Maryam Keshvari 5 , Leila Mehrnoush 2 , Pegah karimi Elizee 6 , Mohammad Gholami Fesharaki 2 , Mansour Asgharinia 1 and Seyed Moayed Alavian 2 , 6
Authors Information
1 Department of Clinical Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Baqiyatallah Research Center for Gastroenterology and Liver Disease, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
3 Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
4 Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, IR Iran
5 Iranian Blood Transfusion Organization Reaserch Center, Tehran, IR Iran
6 Middle East Liver Disease, Tehran, IR Iran
Article information
  • Hepatitis Monthly: August 01, 2013, 13 (8); e11138
  • Published Online: August 12, 2013
  • Article Type: Brief Report
  • Received: March 10, 2013
  • Revised: June 18, 2013
  • Accepted: July 22, 2013
  • DOI: 10.5812/hepatmon.11138

To Cite: Abbasinazari M, Behnava B, Panahi Y, Hajhossein Talasaz A, Salimi S, et al. Plasma Zinc Level in Hepatitis C Patients With or Without Beta Thalassemia Major; Is There Any Difference?, Hepat Mon. 2013 ; 13(8):e11138. doi: 10.5812/hepatmon.11138.

Abstract
Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Chasapis CT, Loutsidou AC, Spiliopoulou CA, Stefanidou ME. Zinc and human health: an update. Arch Toxicol. 2012; 86(4): 521-34[DOI][PubMed]
  • 2. Matsuoka S, Matsumura H, Nakamura H, Oshiro S, Arakawa Y, Hayashi J, et al. Zinc supplementation improves the outcome of chronic hepatitis C and liver cirrhosis. J Clin Biochem Nutr. 2009; 45(3): 292-303[DOI][PubMed]
  • 3. Abbasi Nazari M, Hasani Malayeri S, Pourhoseingholi MA, Mohebi SR, Zali MR. Evaluation of zinc plasma level in Iranian cirrhotic patients due to hepatitis B and hepatitis C. Hepat Mon. 2010; 10(1): 62-4
  • 4. Moriyama M, Matsumura H, Fukushima A, Ohkido K, Arakawa Y, Nirei K, et al. Clinical significance of evaluation of serum zinc concentrations in C-viral chronic liver disease. Dig Dis Sci. 2006; 51(11): 1967-77[DOI][PubMed]
  • 5. Himoto T, Hosomi N, Nakai S, Deguchi A, Kinekawa F, Matsuki M, et al. Efficacy of zinc administration in patients with hepatitis C virus-related chronic liver disease. Scand J Gastroenterol. 2007; 42(9): 1078-87[DOI][PubMed]
  • 6. Abolghasemi H, Amid A, Zeinali S, Radfar MH, Eshghi P, Rahiminejad MS, et al. Thalassemia in Iran: epidemiology, prevention, and management. J Pediatr Hematol Oncol. 2007; 29(4): 233-8[DOI][PubMed]
  • 7. Ataei B, Hashemipour M, Kassaian N, Hassannejad R, Nokhodian Z, Adibi P. Prevalence of anti HCV infection in patients with Beta-thalassemia in isfahan-iran. Int J Prev Med. 2012; 3-23[PubMed]
  • 8. Namazee N, Sali S, Asadi S, Shafiei M, Behnava B, Alavian SM. Real response to therapy in chronic hepatitis C virus patients: a study from iran. Hepat Mon. 2012; 12(9)[DOI][PubMed]
  • 9. Mahyar A, Ayazi P, Pahlevan AA, Mojabi H, Sehhat MR, Javadi A. Zinc and copper status in children with Beta-thalassemia major. Iran J Pediatr. 2010; 20(3): 297-302[PubMed]
  • 10. Mehdizadeh M, Zamani G, Tabatabaee S. Zinc status in patients with major beta-thalassemia. Pediatr Hematol Oncol. 2008; 25(1): 49-54[DOI][PubMed]
  • 11. Jacobes DS, Demott WR, Oxely DK. Leboratory test handbook. 2001; : 1169
  • 12. Yuasa K, Naganuma A, Sato K, Ikeda M, Kato N, Takagi H, et al. Zinc is a negative regulator of hepatitis C virus RNA replication. Liver Int. 2006; 26(9): 1111-8[DOI][PubMed]
  • 13. Grungreiff K, Reinhold D. Zinc: A complementary factor in the treatment of chronic hepatitis C? (Review). Mol Med Rep. 2010; 3(3): 371-5[DOI][PubMed]
  • 14. Kalkan A, Bulut V, Avci S, Celik I, Bingol NK. Trace elements in viral hepatitis. J Trace Elem Med Biol. 2002; 16(4): 227-30[DOI][PubMed]
  • 15. Arcasoy A, Cavdar AO. Changes of trace minerals (serum iron, zinc, copper and magnesium) in thalassemia. Acta Haematol. 1975; 53(6): 341-6[PubMed]
  • 16. Farzin L, Moassesi ME, Sajadi F, Amiri M, Shams H. Serum levels of antioxidants (Zn, Cu, Se) in healthy volunteers living in Tehran. Biol Trace Elem Res. 2009; 129(1-3): 36-45[DOI][PubMed]
  • 17. Grungreiff K, Hebell T, Gutensohn K, Reinhold A, Reinhold D. Plasma concentrations of zinc, copper, interleukin-6 and interferon-gamma, and plasma dipeptidyl peptidase IV activity in chronic hepatitis C. Mol Med Rep. 2009; 2(1): 63-8[DOI][PubMed]
  • 18. Tavajjoh M, Yasrebi J, Karimian N, Olama V. Phytic Acid Concentration and Phytic Acid: Zinc Molar Ratio in Wheat Cultivars and Bread Flours, Fars Province, Iran. J Agric Sci Tech. 2011; 13(5): 743-55
  • 19. Dabbaghmanesh MH, Taheri Boshrooyeh H, Kalantarhormozi MR, Ranjbar Omrani GH. Assessment of zinc concentration in random samples of the adult population in shiraz, iran. Iran Red Crescent Med J. 2011; 13(4): 249-55[PubMed]
  • 20. Jalali MT, Dayer D, Haghighizadeh MH, Karandish M. Very high prevalence of zinc deficiency in elderly hospitalized patients in Ahvaz, Iran. Saudi Med J. 2011; 32(3): 314-5[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments